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Ischemia–reperfusion injuryTraditionally, hydrogen sulﬁde (H2S) was simply considered as a toxic and foul smelling gas, but recently H2S
been brought into the spot light of cardiovascular research and development. Since the 1990s, H2S has been
mounting evidence of physiological properties such as immune modiﬁcation, vascular relaxation, attenuation
of oxidative stress, inﬂammatory mitigation, and angiogenesis. H2S has since been recognized as the third phys-
iological gaseous signaling molecule, along with CO and NO [65,66]. H2S is produced endogenously through sev-
eral key enzymes, including cystathionine β-lyase (CBE), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate
sulfurtransferase (MST)/cysteine aminotransferase (CAT). These speciﬁc enzymes are expressed accordingly in
various organ systems and CSE is the predominant H2S-producing enzyme in the cardiovascular system.
The cystathionine γ-lyase (CSE)/H2S pathway has demonstrated various cardioprotective effects, including anti-
atherosclerosis, anti-hypertension, pro-angiogenesis, and attenuation of myocardial ischemia–reperfusion inju-
ry. CSE exhibits its anti-atherosclerotic effect through 3 mechanisms, namely reduction of chemotactic factor
inter cellular adhesion molecule-1 (ICAM-1) and CX3CR1, inhibition of macrophage lipid uptake, and induction
of smooth muscle cell apoptosis via MAPK pathway. The CSE/H2S pathway's anti-hypertensive properties are
demonstrated via aortic vasodilation through several mechanisms, including the direct stimulation of KATP
channels of vascular smooth muscle cells (VSMCs), induction of MAPK pathway, and reduction of homocysteine
buildup. Also, CSE/H2S pathway plays an important role in angiogenesis, particularly in increased endothelial cell
growth and migration, and in increased vascular network length. In myocardial ischemia–reperfusion injuries,
CSE/H2S pathway has shown a clear cardioprotective effect by preserving mitochondria function, increasing
antioxidant production, and decreasing infarction injury size.
However, CSE/H2S pathway's role in inﬂammation mitigation is still clouded, due to both pro and anti-
inﬂammatory results presented in the literature, depending on the concentration and form ofH2S used in speciﬁc
experiment models.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is anopen access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
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in a family of physiological gaseous signaling molecule along with CO
and NO [65,66] as small molecules that can freely pass through cell
membranes to directly exert biological function by interacting with cel-
lular components.
H2S is produced intrinsically through 3 major enzymes in our body,
namely the CSE, CBS, and 3-MST/CATpathways. This reviewprovides an
overview of the innate production of H2S and several aspects of H2S
function with a cardiocytoprotective focus, particularly on the CSE/H2S
pathway. The CSE/H2S pathway has recently become one of the heated
focuses of cardiovascular disease pathophysiology research.
2. Hydrogen sulﬁde in nature
H2S is a naturally occurring colorless, corrosive, and ﬂammable gas-
eous compound with the characteristic foul odor of rotten eggs under
room temperature at low concentrations up to 30 ppm. The detectable
order threshold for H2S is as low as 1 ppm. The H2S gas is produced
naturally by anaerobic breakdown of sulfur-containing organic matter
and is often associated with petroleum and natural gas reﬁnement,
chemical manufacture, and waste disposal industries.
Biologically, H2S is considered a broad-spectrum poison, acting on
several systems in the body, particularly devastating in the nervous
system. H2S is classiﬁed as a chemical asphyxiant, which forms a
complex bond to the ferric moiety, causing inhibition of mitochondrial
cytochrome oxidase, and thereby arresting aerobic metabolism, similar
to cyanide toxicity. H2S toxicity is further enhanced by its high lipid
solubility which allows it to penetrate easily through phospholipid
membranes. At concentrations above 100 ppm, H2S affects a person's
perception of smell by causing a rapid temporary paralysis of the
olfactory nerves. At concentrations greater than 700 ppm, H2S may
cause sudden death [65,66].
3. Physiological production of H2S
H2S can be detected in a wide range of tissues and organs including
the brain, thoracic aorta, lungs, liver, kidney, ileum, pancreatic islets,
uterus, placenta and umbilical cord, and several other organs, suggest-
ing a pleotropic role for the gaseous transmitter [65,66]. Endogenous
H2S produced in the human body has been attributed to three key en-
zyme pathways, namely the cystathionine γ-lyase (CSE), cystathionine
β-lyase (CBS), and 3-mercaptopyruvate sulfurtransferase (MST)/cysteine
aminotransferase(CAT) pathways. The CSE enzyme is expressed in the
cardiovascular system, predominantly the myocardium and vascular
smooth muscle cells (VMSCs). The CBS enzyme can be found mostly in
the central nervous system. MST and CAT are primarily expressed in
the brain and vascular endothelium [67–77].
Physiological H2S is produced predominantly through themetabolic
pathways of sulfur-containing amino acids. Beginningwithmethionine,
methionine loses a methyl group through the SAM–SAH pathway to
form homocysteine. CBS then converts homocysteine to cystathio-
nine and CSE converts cystathionine to L-cysteine and α-ketobutyrate
[67–77].
Both CSE and CBS are cytosolic pyroxidal-5′-phosphatedependent
enzymes that use L-cysteine as their principal substrate to form H2S.
CBS hydrolyzes L-cysteine to form L-serine and H2S. CSE reacts with
dimerized L-cysteine to form thiocysteine, pyruvate, and NH3.
Thiocysteine in turn may nonenzymatically break down to form
pyruvate and H2S. Alternatively, thiocysteine may engage in a CSE-
mediated reaction with another thiol compound (R-SH) to form Cys-S-R
and H2S [67–77].
On the other hand, MST and CAT are both cytosolic and mitochon-
drial enzymes, with a majority distribution in the mitochondria. CAT
catalyzes L-cysteine and α-ketoglutarate to form 3-mercaptopyruvate
and L-glutamate. 3-mercaptopyruvate may be desulfurized by MST to
form pyruvate and H2S. Alternatively, 3-mercaptopyruvate can beconverted by CAT to thiosulfate and pyruvate. Thiosulfate may then ox-
idize GSH to form GSSG, SO32−, and H2S [67–77] (Fig. 1).
Once H2S is formed, it is quickly broken down through chemical and
enzymatic pathways. Methemoglobin may react with H2S to form
sulfhemoglobin, which acts as a metabolic sink for H2S. Thiol-S-
methyltransferase may methylate H2S to form dimethylsulﬁde and
methanethiol. Furthermore, H2S may be rapidly oxidized to thiosulfate
in themitochondria and subsequently be converted to sulﬁte and sulfate.
4. Physiological concentration of H2S
The range of H2S concentrations offered by the current literature has
proven to be considerably inconsistent. H2S concentration in the human
blood and tissues shown in literature ranges from 2–160 μM [11,25,40,
43,78–81]. Not only is this range so large that it encompasses a differ-
ence of several orders ofmagnitude, the entire detected rangemay itself
be questioned for its validity. Free H2S under the beforementioned con-
centrations is well above the detectable order threshold and yet our
blood does not smell of the characteristic rotten egg smell of H2S. The
most widely used colorimetric detection method of methylene blue
and sulﬁte-sensitive ion-selective electrodes are imperfect in its design.
The detection assays are conducted in the presence of Fe3+ in highly
acidic environments, whichmay liberatemultiple acid-labile sulfur spe-
cies to generate exaggeratedly high values of detected H2S. Other detec-
tions methods such as sulﬁde-sensitive ﬂuorescent dye detection, gas
chromatography, monobromobimane, and polarographic electrodes
have made improvements in detection but differ greatly with detection
limits and accuracy [67,95–98].
However, all the currently utilized detectionmethods all require the
disruption of normal tissue physiology. Measuring H2S from homoge-
nates of tissue samples disregards the actual physiological compart-
mentalization of H2S and cannot be used to reﬂect the localized
concentration of H2S in vivo. Recent developments in reaction-based
ﬂuorescent probe imaging have begun to detect H2S in living cells and
shedding light on the spatial distribution and localized concentration
of H2S [95–105].
5. Cystathionine γ-lyase (CSE)
The crucial enzyme for cardiovascular physiological production
of H2S is cystathionine γ-lyase (CSE), which is the predominantly
expressed in the myocardium and vascular smooth muscle cells. The
murine CSE gene can be traced to a 1.8 kb full-length cDNA containing
an open reading frame of 1197 bp, which encodes a 43.6 kDa protein.
The CSE gene is identiﬁed as a 35 kb mouse genomic fragment through
λ genomic library screening. The CSE gene contains promoter regions,
12 exons, ranging in size from 53 to 579 bp and spanning over 30 kb,
and exon/intron boundaries that are conserved with rat and human
CSE [106] (Table 1).
The CSE protein (EC= 4.4.1.1) is a pyridoxal-phosphate-dependent
enzyme that can be found in high concentrations particularly in the
cytoplasm of heart cells and vascular smooth muscle cells. CSE has an
optimal functional pH of 8.2 and pharmacokinetic parameters KM =
0.5 mM for L-cystathionine, KM = 5.4 mM for homocysteine, and
KM = 3.5 mM for cysteine. CSE is directly regulated by calmodulin and
has broad substrate speciﬁcity.
CSE catalyzes the last step in the trans-sulfuration pathway, using
homocysteine and cysteine as substrates to form lanthionine and hy-
drogen sulﬁde. Further, CSE also acts as cysteine-protein sulfhydrase
to regulate the functions of sulfur-containing protein such as those of
GAPDH, PTPN1 and NF-κB.
The CSE gene is also highly expressed in adult mouse liver and
kidney. In newborn mouse liver and kidney, CSE expression steadily in-
creases and peaks at approximately 3 weeks of age. From there on, CSE
expression in the liver remains constantwhile CSE expression decreases
dramatically in the kidney [106].
Fig. 1.Diagram of the transsulfuration pathway. Themajority of endogenous H2S is produced through the transsulfuration pathway, which utilizes methionine-derived L-cysteine as sub-
strate for CSE and CBE enzymes to form H2S. An alternative route exists where L-cysteine is ﬁrst converted to 3-mercaptopyruvate before reacting with MST enzyme to form H2S. MST=
mercaptopyruvatesulfurtransferase, CAT= cysteine aminotransferase, GNMT= glycine N-methyltransferase, GSS= Glutathione synthase, CSAD= cysteine sulﬁnic acid decarboxylase.
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accession number AY083352, the analysis has shown that the mouse
CSE ORF is 92.5% identical with the rat sequence and is 81.6% identical
with the human sequence [106].6. Atherosclerosis
With respect to cardiovascular diseases, we now focus on the H2S
forming enzyme CSE and cardiovascular pathophysiology. Atheroscle-
rosis is a vascular pathology characterized by plaque formation in
large and medium sized vessel. These plaques increase vessel rigidity,
decrease vascularﬂow, andmay lead to thrombosis in vital organs caus-
ing detrimental effects. Atherosclerosis is the result of a chronic inﬂam-
mation process beginning with vascular remodeling, endothelial
dysfunction, smoothmuscle cell proliferation andmigration, accumula-
tion of cholesterol-rich lipoproteins. Atherosclerotic progression is then
followed by recruitment of lipid-laden macrophages, also known as
foam cells, to form a ﬁbrous cap of collagen and smooth muscle
cells, and a necrotic core rich in lipids [1]. Atherosclerotic lesion rup-
ture may ensue as the result of mechanical damage, overwhelming
plaque burden, or insufﬁciency of smooth muscle cell collagen for-
mation tomaintain plague integrity. This lesion rupture releasesmatrix
metalloproteins and necrotic lipid components causing an inﬂammato-
ry and coagulative vascular response.Table 1
Tissue H2S concentrations.
Sample Subject H2S concentration (μM)
Serum Mouse [55] 23
Rat [40,55] 30–46
Blood Mouse [53,78,88–94] 7–80
Rat [34,82–88] 7–63
Human [11,34,40,43,78–81] 2–110
Brain Rat [11,34] 50–160
Human [11,34] 50–160CSE is suggested to exhibit its anti-atherosclerotic effect through 3
mechanisms, namely the reduction of chemotactic factors inter cellular
adhesion molecule-1 (ICAM-1) and CX3CR1, inhibition of macrophage
lipid uptake, and induction of smooth muscle cell apoptosis via MAPK
pathway [3-5] (Fig. 2).
The circulating form of ICAM-1 has been evaluated as a predictor of
cardiovascular risk and is a marker for vascular inﬂammation in athero-
sclerosis. ICAM-1 is minimally expressed on normal endothelium, but
can be found in signiﬁcant quantities in atherosclerotic plaques [7]. Pro-
liferation of ICAM-1 is associatedwith chemotaxis of inﬂammatory cells.
Mani et al. [1] demonstrated that CSE knock out (CSE KO)mice fed with
atherogenic diet displayed a 30-fold increase in ICAM-1 expression and
increased atherosclerotic plaque size compared to wild type control.
In a separate experiment, overexpression of CSE yielded a signiﬁcant
reduction in CX3CR1 and CX3CL1 expression, as well as reduction
in PPAR-γ dependent CX3CR1-mediated chemotaxis in stimulated
macrophages. In atherogenic-diet mouse model, the CSE inhibitor
DL-propagylglycine(PAG) treatment group displayed signiﬁcant aor-
tic atherosclerosis, including a signiﬁcant increase in brachiocephalic
artery (BCA) plaque size, common carotid artery intima–media com-
plex thickness (IMT), and aortic arch IMT assessed by ultrasound
biomicrocopy compared to control group. Histology analysis also re-
vealed an obvious rise in BCA plaque area and lipid core [2].
Foamcell accumulation is a key part of atherosclerotic plaque forma-
tion. In termsofmacrophage-derived foam cell formation,H2S exerts in-
hibitory effect through the down regulation of SR-A, CD36, and ACAT-1
expression,which attenuates oxidized low density lipoprotein (ox-LDL)
binding and uptake by macrophages [9]. In support, PAG treatment ex-
acerbates the beforementioned factors towards foam cell formation [8].
Vascular smooth muscle cell (VSMC) proliferation and migration is
crucial in the formation of atherosclerotic plaques. In H2S treatment
or CSE overexpression in cultured smoothmuscle cells (SMCs), SMCs
have shown increased phosphorylation of extracellular signal-
regulated kinase (ERK) 1/2, altered expression of cyclin D1 and
p21Cip/WAF-1, activation of caspase 3, and ultimately lead to cell ap-
optosis. ERK is amemberofmammalianmitogen-activatedprotein ki-
nase (MAPK) family and is involved in regulation of cell metabolism
Fig. 2. H2S function in atherosclerosis. The precipitating factors of atherosclerosis include endothelial damage, vascular inﬂammation, and smooth muscle proliferation. H2S functions to
attenuate leukocyte chemotaxis through down regulation of ICAM-1 and CX3CR1/CX3CL1. Moreover, H2S inhibits foam cell formation through down regulating CD36, SR-A, and ACAT-1
surface markers and decreases oxLDL uptake in macrophage. Further, H2S induces vascular smooth muscle apoptosis through up regulating ERK 1/2 and p21Cip/WAF-1 and by down regu-
lating cyclin D1.
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response, and apoptosis [6,10,11,35,73]. Additively, CSE-KOmice has
shown increased SMC proliferation rate in vitro and in vivo, reduced
phosphorylation of ERK1/2 inmesenteric SMCs andmesenteric artery
tissue, and increased susceptibility to apoptosis induced by exoge-
nous H2S at physiologically relevant concentrations [10].
7. Vasorelaxation
Hypertension is a chronicmedical conditionwhere the arterial blood
pressure is elevated above 140/90 mmHg. In all hypertensive illnesses,
90–95% of cases are categorized as primary hypertension, with risk
factors such as advanced age, high sodium intake, obesity, stagnant life-
style, excessive alcohol intake, stress, caffeine consumption, vitamin D
deﬁciency, and a slew of genetic and environmental factors. Hyperten-
sion, as the term implies, puts increased pressure, or stress on the
heart, which could lead to coronary arterial diseases, hypertensive
heart diseases, peripheral arterial diseases, chronic kidney diseases,
stroke, aneurysms, among other diseases.
The CSE/H2S pathway has been shown to exhibit aortic vasodilation
effect through several mechanisms, including the direct stimulation of
KATP channels of VSMC, induction of MAPK pathway, and reduction of
homocysteine buildup, ultimately leading to vasodilation and lowering
of blood pressure.
The primary vasodilatory effect of H2S can be attributed to the direct
stimulation of KATP channels with subsequent hyperpolarization of
aortic vascular smooth muscle in the mesenteric artery, aorta, and
portal vein in rat animal model [10-28]. According to Zhao et al., intra-
venous bolus H2S injection triggered roughly a 30 second transient
decrease in mean arterial blood pressure of 12–30 mm Hg [13]. This
blood pressure lowering effect can be mimicked by penacidil, a KATP
channel opener, and antagonized by glibenclamide, a KATP channel
blocker. Kohn et al. [14] have shown that the rat aortic ring contraction
has a positive dose response to serotonin at 1–10 μmol/L and that com-
bined incubationwith PAG at 10mmol/L for 30min produces amore in-
tensive contraction. Further evidence provided by Zhong et al. [15]
shows that hypertension can be introduced in Wistar rats by oral
administration NG-nitro-L-arginine methyl ester (L-NAME), whichsigniﬁcantly inhibited CSE expression and H2S synthesis in the thoracic
aorta. Other supportive observations include PAG treatment signiﬁcant-
ly increasing blood pressure in Sprague–Dawley rats and mice [11,21],
and the down regulation of CSE/H2S pathway during the development
of hypertension in spontaneously hypertensive rat (SHR) models.
In CSE KO mice, besides an evident 80% reduction in H2S level in
the serum, heart, and aorta, there is observed prominent hypertension
of approximately 18 mm Hg higher than age-matched control at
12 weeks of age and reduced endothelium-dependent vasorelaxation
[11]. However, CSEKOmice conversely showed a heightened sensitivity
to exogenous H2S-induced vasorelaxation and greater H2S-induced
decrease in blood pressure [13].
Additively, CSE's apoptotic effects on VSMC also contribute to the
lowering of blood pressure. The apoptotic effect of CSE/H2S pathway
has already been described in the previous section. With reduced total
VSMC number, the reduction of VMSC contractile force results in an
overall decreased blood pressure [10,11].
CSE's antihypertensive effect is also associated with the reduction of
homocysteine buildup. Homocysteine is a metabolite of methionine
that can be further metabolized to form H2S in the transsulfuration
pathway [17,18]. Hyperhomocysteinemia, or elevated serum homocys-
teine levels, is an independent and graded risk factor associated with
cardiovascular diseases, including hypertension. In hyperhomocystei-
nemia rat model, both serum CSE activity and H2S levels in the myocar-
dium are signiﬁcantly decreased [18]. In a separate study, the 10-week-
old male CSE KOmice group has shown elevated plasma homocysteine
and L-cysteine levels about 18 and 0.8 times, respectively, compared to
age-matched wild type control [17].
8. Angiogenesis
Angiogenesis is a complex biological process characterized by extra-
cellular matrix remodeling and changes in endothelial cell (EC) behav-
ior that lead to increased growth,migration, and assembly into capillary
structures [30–33].
In vitro study evidence shows H2S's proangiogenic effect, Cai et al.
[29] demonstrated that RF/6A transformed EC displayed an up to 100%
increase in cell proliferation and up to 30% increase in migration
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human umbilical vein endothelial cells (HUVECs) to H2S at 60 μM pro-
motes an observable EC growth with 2-fold increase in cell number
and sustained increase in ERK1/2 phosphorylation [30]. Furthermore,
H2S at 60 μM enhances capillary-like structure formation of ECs
cultured on reduced growth factor Matrigel by roughly 34%. EC also
displayed an approximately 4 fold increased cell migration under
60 μM H2S as compared to control.
Another supportive evidence regarding CSE proangiogenic effect is
related to VEGF, a well-established stimulator of angiogenesis. CSE
siRNA transfected EC cells display an average decrease of CSE protein
by 59.8 ± 6.7% and also showing attenuated MAPK, ERK1/2, and p38
pathways. CSE siRNA transfected EC cells stimulatedwith VEGF displays
a 60% decreased cell migration compared to controls under the same
conditions. Further, aortic ring explants from CSE KO shows a roughly
80% decreased new microvessel formation compared to WT control
under both vehicle and VEGF stimulation [31].
In vivo study demonstrates the angiogenic effect of H2S in chick cho-
rioallantoic membrane (CAM) model. Vascular network length is mea-
sured after 48 h of treatment with H2S and PAG. Membranes treated
with 240 pmol/egg H2S show an average 40% increase in vessel length
while administration of 300 μmol/egg PAG displayed a roughly 50%
decrease in vessel branching points and 25% decrease in vessel length
as compared to control [31]. It has longbeen suspected but only recently
brought into light that H2S andNOmay in fact share common pathways
regarding angiogenesis and vasorelaxation [26,27].
Lastly, angiogenesis can be arguably gauged throughwound healing.
In rat burnwoundmodel, wound closure after 1month shows 5% signif-
icant improvement in animal receiving daily topical H2S compared to
WT control. In CSE KO mice, would area were consistently larger than
WT control, suggesting a proangiogenic effect of CSE [30].
9. Myocardial ischemia and reperfusion injuries
Ischemia is a vascular insult characterized by interruption of arterial
blood supply to tissues and organs, causing a shortage of oxygen, glu-
cose, and other essential components required for cellular metabo-
lism and well-being. Causes for ischemia include vasoconstriction,
embolism, thrombosis, or trauma. Ischemia causes tissue damage
through an excessive build-up of metabolic waste, mitochondrial
damage, disruption of cellular membranes, and dispersion of auto-
lyzing and proteolytic enzymes, which causes general dysfunction
and ultimately death of the affected tissues and organs. If a vascular
insult is met with immediatemedical attention, there is a highly like-
ly chance that blood supply may be restored to the ischemic tissues
and organs to prevent total loss of function. However, the reperfusion
of ischemic tissues and organs may cause another type of damage
known as reperfusion injury. Reperfusion injury is mostly a type of
compounded microvascular injury where the reintroduced blood oxy-
gen causes increased production of free radicals and reactive oxygen
species which damage cellular components and the inﬂammatory re-
sponse to the damaged tissue causes swelling and obstruction which
may lead to further ischemia.
In myocardial ischemia and reperfusion injuries, CSE/H2S pathway
has shown a clear cardioprotective effect in reduced ischemic infarction
lesion and increased cell survival [36]. Johansen et al. showed that exog-
enous H2S administration protects against ischemia–reperfusion injury
in a dose-dependent manner observable through the reduction in rat
myocardial infarction size [37]. Elrod et al. further demonstrated that
direct administration of NaHS at 50 mg/kg during reperfusion injury
in an in vivo mouse model preserves mitochondrial function which
leads to a substantial reduction of infarct size [38].
H2S exerts cardioprotective effects against ischemia–reperfusion in-
jury through up regulating Bcl-2/Bax ratio to preserve mitochondrial
function and by enhancing antioxidant enzymes superoxide dismutase
(SOD) and glutathione peroxidase (GSH-Px) to scavenge reactiveoxygen species (ROS), both ultimately result in increased cell survival
[39]. Moreover, H2S serves to activate the Akt–Nrf2 pathway to promote
antioxidant and anti-apoptoticmolecule expression and by inﬂammatory
inhibition through NF-KB dependent path, both leading to tissue survival
[39].
In support of CSE cardioprotective effects, Huang et al. showed that
in an ischemia–reperfusion post-conditioning mouse model, adminis-
tration of 2 mM PAG prior to global ischemia resulted in an infarct size
of 35.9 ± 6.4% compared to infarct size without PAG treatment of
18.3±5.7% [40]. Similarly, Zhu et al. proved that inmyocardial ischemia
ratmodel, infarct sizewas 52.9± 3.5% in vehicle-treated, 62.9± 7.6% in
PAG-treated, and 43.4 ± 2.8% in NaHS-treated (P b 0.05 vs. vehicle)
groups [41].
10. Inﬂammation
A debatable representation of the CSE/H2S pathway is on its effects
regarding inﬂammation. There are separate studies citing both pro
and anti-inﬂammatory effects of CSE/H2S pathway. Regarding the
pro-inﬂammatory effect of CSE/H2S pathway, several researchers have
demonstrated that in mouse models of hind paw edema [51], lipopoly-
saccharide (LPS) induced endotoxemia [52], and cecal ligation and
puncture (CLP) induced sepsis [53,54], administration of H2S donor
drug leads to an increasedMyeloperoxidase (MPO) expression, a mark-
er for tissue neutrophil inﬁltration activity, and upregulation of NF-KB,
which results in a histologically evident increase in tissue inﬂammation
area. Whereas the administration or pretreatment of with PAG resulted
in reducedMPO activity and less tissue inﬂammation. The same pattern
can be seen in caerulein-induced pancreatitis mouse model [55]. Fur-
ther, in CSE KO mouse caerulein-induced pancreatitis model, the CSE
KO mice showed reduced acute pancreatitis inﬂammation and dimin-
ished associated lung injury compared to wild type mouse [56].
However, other researchers have demonstrated anti-inﬂammatory
effect of H2S/CSE pathway. Research with slow releasing H2S donors
such as GYY4137 [6,57] and S-diclofenac [58] demonstrated an anti-
inﬂammatory effect with reduced NF-KB, TNF-α, and MPO expression
in LPS-induced inﬂammation models. Another research showed that
pretreatment or administration of PAG in LPS-treated rats aggregate
liver damage, displaying increased serumAST, liverMPO, and decreased
liver GSH [60]. The existing contradicting observations portray the yet
understood physiological nature of CSE/H2S pathway, and more
research is needed to shed light on this complex pathway. Several re-
searchers have postulated that theremay be a biphasic affect of H2S in re-
lation to either the stage of inﬂammation or the time-concentration of
H2S.
11. Summary
H2S is received as the third gaseous physiological transmitter be-
hind CO and NO and plays an important role in several organ systems
in the body. The CSE/H2S pathway demonstrates cardiovascular anti-
atherogenic effect, vessel dilatory effect, angiogenic effect, inﬂammato-
ry mediator effect, cardioprotective effect against ischemia–reperfusion
injury, and regulates cellular function and humeral response among
others. Although portions of the underlying molecular mechanism of
the CSE/H2S pathway are yet to be clariﬁed, there is continualmounting
evidence and research to provide further insight. To date, researchers
seem to offer a bell-shaped dose–response curve to CSE/H2S effect: at
physiological concentrations, H2S seems to exhibit cytoprotective ef-
fects whereas at higher concentrations, H2S demonstrates detrimental
or cytotoxic effect. Furthermore, recent studies performedwith slow re-
leasing H2S donors in GYY4137 and S-diclofenac seem to emulate phys-
iological conditions more closely and may provide further insight into
the CSE/H2S pathway. There is much effort devoted to clinical disease
model research in correlation with the CSE/H2S pathway, such as in
coronary artery disease, ischemic cardiomyopathy, and chronic total
56 S. Huang et al. / IJC Heart & Vasculature 7 (2015) 51–57occlusion (CTO) of the coronary artery among other life threatening
cardiovascular diseases. In one recent study, new insight into H2S'
cardioprotective effects includes the attenuation of CD11b+Gr-1+mye-
loid migration to reduce post infarct inﬂammation [107]. Furthermore,
observational data from our group shows that in CTO reperfusion injury
model, H2S production after recanalization decreases by approximately
25% in the ﬁrst 24 hour period, followed by a slow increase to approxi-
mately 50% compared to CTO controls. Unsurprisingly, though the de-
crease in H2S and vascular pathology, such as ischemia–reperfusion
injury, hypertension, and atherosclerosis, is observed, we have yet to
grasp the full scope of the CSE/H2S pathway. A clearer understanding
of the CSE/H2S is key to understanding vascular microenvironment
changes and foundation for building future therapeutic strategies
against cardiovascular diseases.
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